<DOC>
	<DOCNO>NCT00393484</DOCNO>
	<brief_summary>Entecavir , 0.5 mg daily , clinical efficacy ( assess undetectable hepatitis B DNA , &lt; 300 copies/mL , Roche Comprehensive Bio-Analytical System Amplicor polymerase chain reaction assay ) comparable ( noninferior ) potentially superior lamivudine , 100 mg daily , adult hepatitis B e antigen-negative chronic hepatitis B virus infection .</brief_summary>
	<brief_title>A Study Korea Entecavir Versus Lamivudine Adults With Chronic Hepatitis B Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Nucleoside nucleotidenaive subject chronic HBV infection Hepatitis B Surface antigen ( HBsAg ) positive ≥6 month Detectable HBsAg HBV DNA ≥ 105 copies/mL PCR ALT 1.3 10 x ULN HBeAg negative , antihepatitis B Virus E antigen antibody ( antiHBeAb ) positive status</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>